Two Biotech Siblings Just Fought Over the Family Business. Only One Won.
Two gene-editing companies born from the same Harvard lab just fought over who gets to treat a rare liver disease. The arbitration ruling has big implications for how the entire CRISPR ecosystem draws battle lines.
Imagine two siblings who grew up in the same house, went to the same schools, and then started competing businesses across the street from each other. Now imagine they're fighting in court over who gets to sell what.
That's basically what just happened between Prime Medicine and Beam Therapeutics, two gene-editing companies that both trace their origins to David Liu's lab at Harvard. A binding arbitration tribunal just ruled in Prime's favor, clearing the company to advance its lead therapy for a rare liver disease without owing Beam a dime. Prime's stock jumped roughly 11–15%. Beam's dropped about 5%.
But this isn't just a corporate spat. It's a signal flare for the entire gene-editing industry.
Same Lab, Different Tools, One Big Problem
To understand the fight, you need to understand the family tree. David Liu's lab at Harvard invented base editing first, then prime editing second. Think of them as cousins in the gene-editing family.
Base editing works like a pencil eraser and a single letter stamp: it chemically swaps one DNA letter for another (say, A to G) at a precise spot. Beam Therapeutics was built around this technology.
Prime editing is more like a word processor's find-and-replace function. It can swap letters, insert short sequences, or delete them. Prime Medicine was spun out to commercialize this newer, more flexible tool.
When Prime was created in 2019, the two companies signed a Collaboration and License Agreement to carve up territory.
Clean and simple, right? Not quite.
The Drug That Started a War
Both companies wanted to treat alpha-1 antitrypsin deficiency (AATD), a rare genetic condition where a single misspelled DNA letter in the liver causes the body to produce a faulty protein. Left untreated, it can destroy the lungs and liver.
The culprit is a specific mutation called : one letter that needs correcting. Beam is developing , a base editor designed to fix that letter. Prime built , a prime editor targeting the exact same mutation.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
